 |
|
Deflazacort vs PrednisoneEffect on Blood Glucose Control in Insulin-Treated Diabetics
Alberto Bruno, MD;
Paolo Cavallo-Perin, MD;
Maurizio Cassader;
Gianfranco Pagano, MD
Arch Intern Med. 1987;147(4):679-680.
Abstract
• Glucocorticoid treatment produces a deterioration of blood glucose control in diabetics. Recent reports have indicated that deflazacort is less diabetogenic than prednisone in healthy subjects. Ten insulin-treated diabetics who required steroid drugs were treated with deflazacort (30 mg/d for four weeks) and prednisone (25 mg/d for four weeks) in randomized, double-blind design after a pretreatment period of four weeks. At the end of each treatment, plasma glucose profile (five determinations per day), hemoglobin A1 level, and insulin requirements were compared. Mean (±SEM) plasma glucose level (139 ± 28 vs 169±32 mg/dL [7.7±1.5 vs 9.4 ± 1.8 mmol/L]) and hemoglobin A1 values (8.81%±1.19% vs 10.71%± 1.17% of total hemoglobin) were significantly lower after deflazacort than after prednisone. Also, insulin requirement was significantly lower after deflazacort than after prednisone (29.3 ± 11.6 vs 47.3 ± 2.0 U/d). These results indicate that deflazacort, when employed in an anti-inflammatory dose equivalent to prednisone, should prove advantageous in insulin-treated diabetics who require steroid treatment.
(Arch Intern Med 1987;147:679-680)
Author Affiliations
From the Institute of Internal Medicine, University of Turin, Italy.
Footnotes
Accepted for publication July 31, 1986.
Reprint requests to Istituto di Medicina Interna, C. Polonia 14, 10126 Torino, Italy (Dr Pagano).
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data
Da Silva et al.
Ann Rheum Dis 2006;65:285-293.
ABSTRACT
| FULL TEXT
Glucose Intolerance After Short-term Administration of Corticosteroids in Healthy Subjects: Prednisone, Deflazacort, and Betamethasone
Pagano et al.
Arch Intern Med 1989;149:1098-1101.
ABSTRACT
|
